• English
  • 中文繁体
  • 中文简体
Hi,
moomoo ID:NaN
Log Out
donwloadimg

Download App

Log in to access Online Inquiry
Quotes
Detailed Quotes
Company Overview
Company ProfileCompany Executives
Financial Analysis
Main CompositionKey IndicatorsFinancial Statement
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > BLUE bluebird bio > Detailed Quotes

BLUE bluebird bio

4.343
-0.058-1.31%
Trading Session 06/27 13:39 ET
High
4.400
Open
4.390
Turnover
14.79M
Low
4.070
Pre Close
4.400
Volume
3.51M
Market Cap
310.29M
P/E(TTM)
Loss
52wk High
20.553
Shares
71.45M
P/E(Static)
Loss
52wk Low
2.865
Float Cap
291.19M
Bid/Ask %
-16.92%
Historical High
152.883
Shs Float
67.06M
Volume Ratio
0.23
Historical Low
2.865
Dividend TTM
--
Div Yield TTM
450
P/B
1.18
Dividend LFY
--
Div Yield LFY
10362.69%
Turnover Ratio
5.23%
Amplitude
7.50%
Avg Price
4.215
Lot Size
1
Float Cap
291.19M
Bid/Ask %
-16.92%
Historical High
152.883
Shs Float
67.06M
Volume Ratio
0.23
Historical Low
2.865
Dividend TTM
--
P/B
1.18
Dividend LFY
--
Turnover Ratio
5.23%
Amplitude
7.50%
Avg Price
4.215
Lot Size
1
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast

No Data

News

Comment

News

Announcement

All

Earnings Report

Related Transactions

Changes In Ownership

Major Events

Other

Company Overview More
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with β-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
CEO： Obenshain, Andrew
Market： NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...